SCHEMBL17459119

SCHEMBL17459119

COc1ccc(Cn2cc(N)c(C(F)(F)F)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.43
HSP90AB1 P08238 2/20 0.43
GAA P10253 1/20 0.43
KLKB1 P03952 5/20 0.43
AADAT Q8N5Z0 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
PTGS2 P35354 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
CMA1 P23946 1/20 0.40
DGAT1 O75907 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20521155 0.84 KLKB1 (0.43) HSP90AA1HSP90AB1GAAKLKB1AADAT
SCHEMBL21420053 0.83 HSP90AA1 (0.43) HSP90AA1HSP90AB1GAAKLKB1AADAT
SCHEMBL17459135 0.82 LMNA (0.49) KLKB1MEN1NPC1RAB9AKMT2A
SCHEMBL7258447 0.81 MEN1 (0.47) HSP90AA1HSP90AB1AADATMEN1NPC1
SCHEMBL20521837 0.81 GAA (0.53) GAAKLKB1AADATDGAT1
SCHEMBL14150628 0.81 KLKB1 (0.48) HSP90AA1HSP90AB1GAAKLKB1AADAT
SCHEMBL1048741 0.81 KLKB1 (0.48) HSP90AA1HSP90AB1GAAKLKB1AADAT
SCHEMBL3696648 0.80 GAA (0.43) HSP90AA1HSP90AB1GAAKLKB1AADAT
SCHEMBL3696651 0.80 GAA (0.46) HSP90AA1HSP90AB1GAAKLKB1AADAT
SCHEMBL28170666 0.80 GAA (0.43) HSP90AA1HSP90AB1GAAKLKB1AADAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087442-A1 AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 WO disclosed
CN-107074814-A Glucose transport inhibitor 拜耳制药股份公司 2017-08-18 CN disclosed
US-20170226081-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-08-10 US disclosed
US-20170226081-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-08-10 US disclosed
EP-3172192-A1 GLUCOSE TRANSPORT INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2017-05-31 EP disclosed
WO-2016012481-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-01-28 WO disclosed
WO-2016012481-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226081-A1 GLUCOSE TRANSPORT INHIBITORS SLC2A1, SLC2A2, SLC2A4 HSP90AA1 975/4885HSP90AB1 655/4885GAA 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.